Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Product Overview:
CD33 is a transmembrane receptor and member of the sialic acid-binding immunoglobulin-type (Ig-type) lectin (SIGLEC) family.{54696} It is composed of N-terminal extracellular Ig-like variable (IgV) and Ig-like constant 2 (IgC2) domains, as well as intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM) and ITIM-like (ITL) domains. CD33 has two isoforms formed via alternative splicing, a full-length form and CD33m, which lacks the IgV-like domain.{54697} The full-length form is expressed on myeloid progenitor cells and in microglia while CD33m is found in myeloid cells and lymphocytes.{54696,54697} CD33 is an inhibitory receptor activated by binding of sialic acid-containing molecules, such as glycolipids and glycoproteins, to the IgV domain, which stimulates phosphorylation of tyrosine in the ITIM domain, leading to recruitment of Src homology 2 domain-containing phosphatases (SHPs) and internalization of the CD33-ligand complex.{54698} Signaling downstream of CD33 inhibits phagocytosis and cytokine release from immune cells, as well as regulates immune cell growth and survival. CD33 protein is found on patient-derived acute myeloid leukemia (AML) progenitor cells but not non-cancerous stem cells.{54699} A SNP in CD33 is associated with, and considered a risk factor for, Alzheimer’s disease.{54696} Cayman’s CD33 Chimeric Monoclonal Antibody was produced recombinantly from the original hP67.6 antibody sequence and can be used for flow cytometry (FC) and immunofluorescence (IF) applications. The hP67.6 antibody was generated by humanization of the murine P67.6 clone raised against CD33-transfected FMT9S5 cells of human origin.{68192}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.